TY - JOUR
T1 - Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation
AU - Bove-Fenderson, Erin
AU - Urano, Ryo
AU - Straub, John E.
AU - Harris, David A.
N1 - Funding Information:
This work was supported by National Institutes of Health (NIH) Grant R01 NS065244 (to D. A. H.), National Science Foundation Grant CHE-1362524 and NIH Grant R01 GM107703 (to J. E. S.), and National Research Service Award Fellowship 5F31NS090747 (to E. B-F.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2017/10/13
Y1 - 2017/10/13
N2 - Oligomeric forms of the amyloid- (A) peptide are thought to represent the primary synaptotoxic species underlying the neurodegenerative changes seen in Alzheimer’s disease. It has been proposed that the cellular prion protein (PrPC) functions as a cell-surface receptor, which binds to A oligomers and transduces their toxic effects. However, the molecular details of the PrPC–A interaction remain uncertain. Here, we investigated the effect of PrPC on polymerization of A under rigorously controlled conditions in which A converts from a monomeric to a fibrillar state via a series of kinetically defined steps. We demonstrated that PrPC specifically inhibited elongation of A fibrils, most likely by binding to the ends of growing fibrils. Surprisingly, this inhibitory effect required the globular C-terminal domain of PrPC, which has not been previously implicated in interactions with A. Our results suggest that PrPC recognizes structural features common to both A oligomers and fibril ends and that this interaction could contribute to the neurotoxic effect of A aggregates. Additionally, our results identify the C terminus of PrPC as a new and potentially more druggable molecular target for treating Alzheimer’s disease.
AB - Oligomeric forms of the amyloid- (A) peptide are thought to represent the primary synaptotoxic species underlying the neurodegenerative changes seen in Alzheimer’s disease. It has been proposed that the cellular prion protein (PrPC) functions as a cell-surface receptor, which binds to A oligomers and transduces their toxic effects. However, the molecular details of the PrPC–A interaction remain uncertain. Here, we investigated the effect of PrPC on polymerization of A under rigorously controlled conditions in which A converts from a monomeric to a fibrillar state via a series of kinetically defined steps. We demonstrated that PrPC specifically inhibited elongation of A fibrils, most likely by binding to the ends of growing fibrils. Surprisingly, this inhibitory effect required the globular C-terminal domain of PrPC, which has not been previously implicated in interactions with A. Our results suggest that PrPC recognizes structural features common to both A oligomers and fibril ends and that this interaction could contribute to the neurotoxic effect of A aggregates. Additionally, our results identify the C terminus of PrPC as a new and potentially more druggable molecular target for treating Alzheimer’s disease.
UR - http://www.scopus.com/inward/record.url?scp=85031320929&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031320929&partnerID=8YFLogxK
U2 - 10.1074/jbc.M117.789990
DO - 10.1074/jbc.M117.789990
M3 - Article
C2 - 28842494
AN - SCOPUS:85031320929
SN - 0021-9258
VL - 292
SP - 16858
EP - 16871
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 41
ER -